Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
about
Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection PathwaysAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesSRC: marker or actor in prostate cancer aggressivenessPhenotypic characterization of prostate cancer LNCaP cells cultured within a bioengineered microenvironmentIGF-IR Targeted Therapy: Past, Present and FutureSynthetic androgens as designer supplementsMale germ cell-specific RNA binding protein RBMY: a new oncogene explaining male predominance in liver cancerLestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cellsRegulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2.The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesA Class of Semiparametric Mixture Cure Survival Models with Dependent Censoring.Heparanase promotes human gastric cancer cells migration and invasion by increasing Src and p38 phosphorylation expression.The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease.Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.A potential novel spontaneous preterm birth gene, AR, identified by linkage and association analysis of X chromosomal markers.Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression.N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.Constitutive activity of the androgen receptor.Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.Positive selection in the evolution of cancer.Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression.Nonreceptor tyrosine kinases in prostate cancer.The androgen receptor as an emerging target in hepatocellular carcinomaA twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factorsA randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitroProstate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Targeting the IGF1 axis in cancer proliferation.Non-Genomic Actions of the Androgen Receptor in Prostate CancerMetformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.Differential Effects of Hormones on Cellular Metabolism in Keratoconus In Vitro.Androgen function in the pathophysiology and treatment of male Huntington's disease patients.Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapyMolecular effects of supraphysiological doses of doping agents on health.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
P2860
Q26742114-F5F1AC10-A84C-4B35-97BE-0DFACB5D1B9FQ26866135-6637AC67-3C36-4EAB-B749-B4EEF3B8B23BQ27012541-4D696134-74CB-45FF-B6A2-4C3752606863Q27335274-D308AE6F-C9E6-4558-B64A-844389126399Q28082127-876B6F18-B474-4FEC-AF3A-C66883276BA5Q28263449-5FC56BBD-4947-45C1-8B9B-D5D1AF81729BQ28477819-D263C7D0-7C82-40A9-BBC6-0495C6609846Q28482432-F40E2467-2197-4105-BC9E-434A8543997EQ30410739-9BBF80B7-DA17-4915-84D8-0BD1804C04A8Q30495758-421CFCEE-A398-4FEE-8D5A-A7A639A7A81FQ33584227-E0ED4CA5-AC6E-4FFF-BCF3-A3408268FBEDQ33658023-6279C5B2-5FED-4E2D-8D64-5B378161D774Q34060554-EE7F1128-5901-4136-A564-8BBD4AFAB926Q34371234-EE2865BF-E5F2-4415-9A72-BF50DB12F799Q34429213-4C0B6BD3-3D64-41B0-9C1A-FA54CE9C73EBQ34431333-31092E44-E6E4-4355-8A25-D36F6B8AE4EDQ34507367-45F03C96-A9D7-4F3C-AF51-35DF46B0F32DQ34526408-3E213309-14F5-4E45-8582-CFE720307599Q34749943-9634E3A7-0CA3-4332-80FE-29BF3483B4CCQ34775572-C2CB20DE-64FC-4FB4-933B-F8897F5B469CQ35112059-F66EB23D-8A9B-431C-89EB-94870EAB910FQ35588394-9DBFA52D-CC51-4293-8424-9CC0F05FC887Q35823852-CB5F80D4-609F-4FE0-A99F-8123D91C4478Q36500617-9A3C0C9C-5074-4113-B1AC-439DF3768D0AQ36603857-8EEF9E69-C5D7-4E82-BFE0-5DF953225C11Q36714276-064D8A68-EC8C-4797-8B27-C0227C39320EQ36759212-2BFD9527-9112-4960-A863-D5807CC32F84Q37031766-422197F5-E9A8-40F8-A7DF-0D5BE43EDDDFQ37105231-AA856116-7A57-49F7-BB79-80AADC8385DBQ37258981-F912CB2B-2039-4859-B77E-A51898A51FBEQ37332423-DE4E9B86-8509-478F-BF7F-4158A2BC7033Q37537958-B78FE94A-1DF3-43C5-A0E4-247CE0E1F75FQ37575541-5CA0620E-137A-46C5-9C6D-69C7CA6E10B4Q37588620-416564D6-15E3-4E1C-917F-1F3FA71EF77EQ37648017-B93042AF-30F9-4042-86E0-BEE10DE97A75Q37648847-FA29E15F-7CF2-4AD0-AAC5-CC098AD63DE4Q38016572-335DBF40-772B-4FC6-A7D0-E5733AAB9E70Q38177688-76493307-E891-4A91-A07C-473769D31255Q38383101-C4002B9F-0757-49DA-A629-EEA7ED4095D9Q38641329-7541A12C-70A8-41F9-859C-51C955146677
P2860
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@ast
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@en
type
label
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@ast
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@en
prefLabel
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@ast
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
@en
P2093
P50
P1433
P1476
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells
@en
P2093
Francesco Frasca
Giuseppe Pandini
Marco Marcelli
Rossana Mineo
P304
P356
10.1158/0008-5472.CAN-04-1837
P407
P577
2005-03-01T00:00:00Z